Key result
Second-generation LMWHs like bemiparin match enoxaparin efficacy for surgical VTE prophylaxis.
Why the study?
Venous thromboembolism is a major cardiovascular disease with surgery being a well-known risk factor, requiring careful assessment of individual thromboembolism and bleeding risks to guide pharmacological prophylaxis.
Does pharmacological prophylaxis with second-generation low-molecular-weight heparins prevent venous thromboembolism in surgical patients?
Does pharmacological prophylaxis with second-generation low-molecular-weight heparins prevent venous thromboembolism in surgical patients?
This review highlights second-generation low-molecular-weight heparins like bemiparin as effective first-line agents for VTE prophylaxis in surgical patients.
Answers are grounded in this paper and cite their sources.
May support bemiparin as enoxaparin alternative for surgical VTE prophylaxis; leaves open dedicated RCTs.
Venous thromboembolism is the third most common cardiovascular disease after myocardial infarction and stroke, affecting a significant percentage of the population. Surgery is a well-known risk factor for venous thromboembolism, and the more serious the surgical procedure, the higher the risk of developing it. This review provides an analysis of the main risk factors for venous thromboembolism in operated patients, the role of optimizing the balance of thromboembolism/bleeding risk in determining the individual risks of surgical patients, and a comparative analysis of therapy for venous thromboembolism using drugs with antiplatelet and anticoagulant activity. A summary of the data available in the scientific literature shows that, despite the existing variety of antiplatelet and anticoagulant drugs, the second-generation low-molecular-weight heparins, with bemiparin as A prominent representative, are currently the first-line drugs for the pharmacoprophylaxis of venous thromboembolism in the context of major surgical interventions, which has been confirmed by numerous clinical trials conducted around the world. Special clinical studies have confirmed the equivalence of efficacy and safety, and in some cases, also certain advantages of second-generation drugs (for example, bemiparin) in comparison with enoxaparin, the most common first-generation drug currently used in clinical practice in surgical/oncological patients. The duration of bleeding prophylaxis with bemiparin and other low-molecular-weight heparins in surgical/oncological patients, according to the data of most clinical trials with an appropriate level of evidence, may range from 1–2 weeks up to 35 days, depending on the individually assessed balance of thromboembolism/bleeding risks.
No takes yet. Share an insight, caveat, or question.
Savoliuk et al. (2025) conducted a review in Venous thromboembolism in surgical patients. Second-generation low-molecular-weight heparins (e.g., bemiparin) vs. First-generation drugs (e.g., enoxaparin) was evaluated. Second-generation low-molecular-weight heparins, particularly bemiparin, are effective first-line drugs for venous thromboembolism prophylaxis in surgical patients, showing equivalence to enoxaparin.
Synapse has enriched 10 related papers. Consider them for comparative context: